Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $163

Benzinga Newsdesk www.benzinga.com Negative 88.2%

Neg 88.2% Neu 0% Pos 0%

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $165 to $163.